RxDoctor Payments Data

Brittany Jang

Physician Assistant · Greenbrae, CANPI 1063972339

Payments from drug & device makers

$3,670in general payments, 2019–2025

Across 135 payments — averaging $27.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$757
  • AbbVie$531
  • Astellas Pharma US Inc$380
  • Johnson & Johnson$257
  • Intuitive Surgical$191
  • Ferring Pharmaceuticals Inc.$158
  • plus $1K from 26 others

What the payments were for

  • Food & beverage$3,61599%
  • Education$551%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,670 in reported general payments places this provider in the 85th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$120,532
Medicare patients
520
Services billed
1,261

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron262$251,496
GemtesaVibegron113$119,881
Tamsulosin Hcl1,139$22,680
Finasteride634$11,635
Methenamine Hippurate89$9,267
Testosterone73$6,526
Oxybutynin Chloride ErOxybutynin Chloride141$4,727
Potassium Citrate ErPotassium Citrate30$4,465
Tolterodine Tartrate ErTolterodine Tartrate32$2,503
NitrofurantoinNitrofurantoin Macrocrystal45$2,350
Alfuzosin Hcl ErAlfuzosin Hcl93$2,029
Testosterone Cypionate33$1,442
Trospium Chloride25$1,152
Dutasteride46$1,112
Trimethoprim11$813

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$380$251,496262 claims
Sumitomo Pharma America, Inc.Gemtesa$757$119,881113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Greenbrae

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →